Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month High – Here’s What Happened

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $5.05 and last traded at $4.89, with a volume of 2554767 shares changing hands. The stock had previously closed at $4.83.

Analyst Ratings Changes

A number of research analysts have commented on the company. Lifesci Capital began coverage on Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Guggenheim raised their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Finally, Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Compass Therapeutics Price Performance

The firm has a market capitalization of $869.74 million, a price-to-earnings ratio of -10.87 and a beta of 1.48. The firm has a 50 day moving average price of $3.93 and a 200-day moving average price of $3.11.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Equities research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock worth $463,000 after acquiring an additional 5,590 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Compass Therapeutics by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock worth $566,000 after purchasing an additional 11,689 shares during the last quarter. Deutsche Bank AG acquired a new position in shares of Compass Therapeutics during the first quarter worth $194,000. Nuveen LLC acquired a new position in shares of Compass Therapeutics during the first quarter worth $579,000. Finally, American Century Companies Inc. purchased a new position in Compass Therapeutics in the first quarter valued at $140,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.